All In MedTech

Device Trial Radar · NCT04516772

STAAR Visian Toric ICL Post-Approval Study

Post-Approval Study of the Visian Toric Implantable Collamer Lens

Last checked: Nov 20, 2026Latest source record: Mar 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

125

Actual

Start

Jul 21, 2020

Primary completion

Dec 11, 2024

Study completion Dec 11, 2024

Sponsor

Lead sponsor
Staar Surgical CompanyNot on our public-company list
Sponsor type
Industry
First posted
Aug 18, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 21 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate the long term (i.e. 24 months) clinical performance of the Visian® Toric Implantable Collamer® Lens (ICL).

Conditions

  • Myopic Astigmatism

Interventions

  • Visian TICLDevice

    The Visian TICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Axis Orientation of the TICLTime frame: 18 to 24 months postoperative

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Aloha Laser Vision, LLC

    Honolulu, Hawaii

  • Price Vision Group,

    Indianapolis, Indiana

  • Solomon Eye Physicians and Surgeons/Bowie Vision Institute

    Bowie, Maryland

5 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.